Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509598 · ClinicalTrials.gov registry record · Phase 2
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
A Phase 2 study of Melanoma and Rhabdomyosarcoma, sponsored by Cardinal Health 414.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT02509598: Completed Phase 2 study of Melanoma and Rhabdomyosarcoma, sponsored by Cardinal Health 414.
NCT02509598 is a Phase 2 study of Melanoma and Rhabdomyosarcoma that has completed, run by Cardinal Health 414. The registered enrollment target is 24 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02509598, a Phase 2 study of Melanoma and Rhabdomyosarcoma, has completed, sponsored by Cardinal Health 414.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
Open label, non-randomized, multi-center, within-subject comparative study to evaluate the tolerability and the diagnostic utility of Lymphoseek with optional comparison to VBD in pediatric subjects with melanoma, rhabdomyosarcoma, or other solid tumor. Subject age will range from neonatal through 17 years.
Conditions Studied
Interventions
- PROCEDURE Lymph Node Mapping
- DRUG Tc99m tilmanocept
- DRUG Vital Blue Dye (optional)
Study Locations (6)
Florida
- Nemours Children's Specialty Care - Jacksonville
- Nemours Children's Hopsital - Orlando
Ohio
- Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Children's Hospital of Pittsburgh - Pittsburgh
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-08 |
| Est. Completion | 2019-03-06 |
| Phase | Phase 2 |
What the finished NCT02509598 record still lists
NCT02509598 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Lymph Node Mapping is the first listed.
NCT02509598 lists 6 locations in 4 states (Florida, Ohio, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02509598 about?
NCT02509598 is a clinical study titled "A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping". Open label, non-randomized, multi-center, within-subject comparative study to evaluate the tolerability and the diagnostic utility of Lymphoseek with optional comparison to VBD in pediatric subjects with melanoma, rhabdomyosarcoma, or other solid tumor. Subject age will range from neonatal through 1...
What is the current status of trial NCT02509598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-08. Estimated completion is 2019-03-06.
What conditions does trial NCT02509598 study?
This clinical trial studies the following conditions: Melanoma, Rhabdomyosarcoma.
What interventions are being tested in trial NCT02509598?
The interventions under investigation include: Lymph Node Mapping (PROCEDURE), Tc99m tilmanocept (DRUG), Vital Blue Dye (optional) (DRUG).
Who is sponsoring clinical trial NCT02509598?
This trial is sponsored by Cardinal Health 414, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02509598 being conducted?
This trial has 6 study locations across Florida, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02509598's enrollment target sits among peer trials
24 219th of 266 higher than 46 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia